1-3 of 3
Xiangdong Zhou
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

No Evidence of BCMA Expression Loss or Systemic Immune Impairment after Treatment with the BCMA-Targeted Antibody-Drug Conjugate (ADC) Belantamab Mafodotin (Belamaf) in the DREAMM-1 and DREAMM-2 Trials of Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Free
Daniel E. Lowther, E. Andres Houseman, Gang Han, Eleni Kleanthous, Dawson Knoblock, Xiangdong Zhou, Shreyan Banerjee, Sagar Patel, David Figueroa
Journal: Blood
Blood (2022) 140 (Supplement 1): 611–613.
https://doi.org/10.1182/blood-2022-157767
Published: 2022
Journal Articles

ALPHA2 Study: ALLO-501A Allogeneic CAR T in LBCL, Updated Results Continue to Show Encouraging Safety and Efficacy with Consolidation Dosing

Free
Lazaros J. Lekakis, Frederick L. Locke, Michael Tees, Sattva S. Neelapu, Shahbaz A. Malik, Mehdi Hamadani, Matthew J. Frank, Leslie L. Popplewell, Jeremy S. Abramson, Sven de Vos, Javier Munoz, Chu Ri Shin, Arun Balakumaran, Lynn Loomis-Navale, Lovely Goyal, Xiangdong Zhou, David B. Miklos
Journal: Blood
Blood (2021) 138 (Supplement 1): 649.
https://doi.org/10.1182/blood-2021-146045
Published: 2021
Journal Articles

Universal: An Allogeneic First-in-Human Study of the Anti-Bcma ALLO-715 and the Anti-CD52 ALLO-647 in Relapsed/Refractory Multiple Myeloma

Free
Sham Mailankody, MBBS, Jeffrey V. Matous, MD, Michaela Liedtke, MD, Surbhi Sidana, MD, Shahbaz Malik, MD, Rajneesh Nath, MD, Olalekan O. Oluwole, MBBS, MPH, Erin E. Karski, Wade Lovelace, Xiangdong Zhou, PhD, Srinand Nandakumar, PhD, Arun Balakumaran, MD PhD, Parameswaran Hari, MD MRCP
Journal: Blood
Blood (2020) 136 (Supplement 1): 24–25.
https://doi.org/10.1182/blood-2020-140641
Published: 2020